ARCHIVE
August 25th 2009: Ola Levin elected to Board of Directors
Ola Levin, with over 30 years of experience from the Scandinavian pharmaceutical and biotech industry, has been elected to Scandinavian Outcomes AB Board of Directors. With Mr Levin's experience from senior management positions in the life science industry, the company's will stengthen it's business development going forward.
June 9th, 2009: Real world studies - Phase V
Scandinavian Outcomes designs and conducts real life studies Phase V in collaboration with the life science industry and healthcare professionals. The increased focus on this type of studies is widely acknowledged by the medical community. A recently conducted seminar focused on the need for ongoing stakeholder dialog on this issue. Read more about the seminar (opens new window)
Scandinavian Outcomes designs and conducts real life studies Phase V in collaboration with the life science industry and healthcare professionals. The increased focus on this type of studies is widely acknowledged by the medical community. A recently conducted seminar focused on the need for ongoing stakeholder dialog on this issue. Read more about the seminar (opens new window)
3 March 2009: Meet us in Florida!
Scandinavian Outcomes will present a workshop on 20th May 2009 at the ISPOR 14th Annual International Meeting in Orlando. The workshop will discuss how to generate real world data before market access, when collecting clinical and health economic data from a compassionate use programme. An innovative approach for orphan drugs is to conduct a compassionate use programme with a separate, parallel disease registry to generate and collect treatment data prior to marketing approval of a drug.
Read more about the 14th Annual International Meeting at ISPOR:s website (opens new window)
Scandinavian Outcomes will present a workshop on 20th May 2009 at the ISPOR 14th Annual International Meeting in Orlando. The workshop will discuss how to generate real world data before market access, when collecting clinical and health economic data from a compassionate use programme. An innovative approach for orphan drugs is to conduct a compassionate use programme with a separate, parallel disease registry to generate and collect treatment data prior to marketing approval of a drug.
Read more about the 14th Annual International Meeting at ISPOR:s website (opens new window)
13 February 2009: IPULS certified course
Our training course within observational research "Att planera och genomföra en observationsstudie" is now certified by IPULS, the institute that critically reviews and certifies education for continuing professional development and postgraduate education of physicians in Sweden. The course is offered to both clinical staff and to our clients within the life science industry that work with observational studies. We offer this course normally as a one day course, however the duration and content can be tailored to meet the needs and requirements of the audience.
Read more about this training course on the IPULS website (opens new window)